Cover image of the article: Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran

Image Credit:Hepat Mon

Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran

Authors

Seyed Moayed AlavianSeyed Moayed Alavian ORCID1,*, Kamran B. Lankarani 2, Mario Rizzetto3, Alfredo Marzano 4, Mohsen Moghadami 5, Saman Nik-Eghbolian6, Amin Bahrani6
1Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, alavian@thc.ir, IR Iran
2Health Policy Research Center, Shiraz University of Medical Sciences, IR Iran
3Department of Gastroenterology, Molinette University of Torino, Italy
4Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Italy
5HIV/AIDS Research Center, Shiraz University of Medical Sciences, IR Iran
6Shiraz Organ Transplant Unit, Namazee Hospital, Shiraz University of Medical Sciences, IR Iran
*Corresponding Author: Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Ground floor of Baqiyatallah Hospital, Mollasadra Ave., Vanak Sq. P.O. Box 14155?3651, alavian@thc.ir, IR Iran. Tel: +98-2181262072. Fax: +98-2181262072. Email: alavian@thc.ir

Hepatitis Monthly:Vol. 12, issue 12; 8094
Published online:Dec 30, 2012
Article type:Meeting Report
Received:Aug 01, 2012
Accepted:Sep 08, 2012
How to Cite:Alavian SM, B. Lankarani K, Rizzetto M, Marzano A, Moghadami M, et al. Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran. Hepat Mon. 2012;12(12):8094. doi: https://doi.org/10.5812/hepatmon.8094

Abstract

Hepatitis B infection is the main cause of liver related mortality in many countries including Iran. Liver transplantation in cirrhosis due to HBV infection before 1990 was an absolute contraindication. Recurrent infection was a significant event in post liver transplant setting and resulted in increased risk of graft failure and death except successful transplanted individuals. Advances in antiviral prophylaxis have now made graft reinfection majority patients as a rare event. Graft and patient survival have been improved significantly during the past two decades, and consequences of transplantation for hepatitis B virus are now superior to those achieved for most other indications. This has encouraged many centers including the major liver transplantation center of Iran, in Shiraz, to provide liver transplantation to more patients with HBV related end stage liver disease. Management of these patients begins before transplantation along with special care after transplantation. There are some myths and doubts in the management of these patients and one should always balance the cost and efficiency. One of the major concerns is the high economic and social cost of recurrence and all possible efforts should be performed to avoid the ominous consequences of reinfection. Having a clear scientific grasp on the management of HBV cirrhosis before and after liver transplantation, options and protocols, and changing the concept which HBV infected are contraindicated ones for liver transplantation, and future hopes in increasing patients survival after liver transplantation using the new nucleosides analogues and availability of hepatitis B immunoglobulin in the transplantation setting. This scientific report paper outlines the insights communicated at the HBV and liver transplantation symposium during 10th Congress of the Iranian Society for Organ Transplantation, May 2011, Shiraz, Iran.

Highlights

Full Text

Full text is available in PDF

Copyright

© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

1
Jan
2013
Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature

Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature

Seyed Mohsen Dehghani,
Seyed Ali Reza Taghavi,
Bita Geramizadeh,
Saman Nikeghbalian,
Nima Derakhshan,
Abdorrasoul Malekpour
,et al.

Dehghani SM, Taghavi SAR, Geramizadeh B, Nikeghbalian S, Derakhshan N, et al. Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature. Hepat Mon. 2013;13(1):e6609. doi: https://doi.org/10.5812/hepatmon.6609

18
May
2021
Clinical Course and Outcome of Liver Transplantation in Patients with Hepatitis C in Iran

Clinical Course and Outcome of Liver Transplantation in Patients with Hepatitis C in Iran

Fardad Ejtehadi,
Paymun Farahvashi,
Alireza Shamsaeefar,
Ramin Niknam,
Gholam Reza Sivandzadeh,
Ladan Aminlari
,et al.

Ejtehadi F, Farahvashi P, Shamsaeefar A, Niknam R, Sivandzadeh GR, et al. Clinical Course and Outcome of Liver Transplantation in Patients with Hepatitis C in Iran. Hepat Mon. 2021;21(3):e108405. doi: https://doi.org/10.5812/hepatmon.108405

24
Oct
2012
Epidemiological Pattern of Hepatitis B and Hepatitis C as Etiological Agents for Hepatocellular Carcinoma in Iran and Worldwide

Epidemiological Pattern of Hepatitis B and Hepatitis C as Etiological Agents for Hepatocellular Carcinoma in Iran and Worldwide

Ahmed Zidan,
Hubert Scheuerlein,
Silke Schle,
Utz Settmacher,
Falk Rauchfuss

Zidan A, Scheuerlein H, Schle S, Settmacher U, Rauchfuss F. Epidemiological Pattern of Hepatitis B and Hepatitis C as Etiological Agents for Hepatocellular Carcinoma in Iran and Worldwide. Hepat Mon. 2012;12(10):6894. doi: https://doi.org/10.5812/hepatmon.6894

1
Jan
2008
Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin

Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin

Mehdi Dehghani

Dehghani M. Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin. Shiraz E-Med J. 2008;9(1):. doi:

30
Jun
2011
Role of living donor liver transplantation in the treatment of hepatitis C virus infection

Role of living donor liver transplantation in the treatment of hepatitis C virus infection

Georgios Tsoulfas,
Polyxeni Agorastou

Tsoulfas G, Agorastou P. Role of living donor liver transplantation in the treatment of hepatitis C virus infection. Hepat Mon. 2011;11(6):. doi:

More by these authors

Seyed Moayed AlavianPubMedScholar
Kamran B. LankaraniPubMedScholar
Mario RizzettoPubMedScholar
Alfredo MarzanoPubMedScholar
Mohsen MoghadamiPubMedScholar
Saman Nik-EghbolianPubMedScholar
Amin BahraniPubMedScholar
Share
Cited by
Metrics